Resource for Molecular Imaging Agents in Precision Medicine

精准医学分子成像剂资源

基本信息

批准号：
10226206
负责人：
MARTIN G POMPER
金额：
$ 117.95万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-09-15 至 2024-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10226206
关键词：
Address Autologous Transplantation Biological Biological Markers Biomedical Technology Brain imaging CAR T cell therapy Cancer Vaccines Caring Cell Line Cell Transplantation Cell surface Cells Chemical Agents Chemicals Chemistry Clinic Clinical Collaborations Communities Data Detection Development Discipline of Nuclear Medicine Education Environment FOLH1 gene Generations Genetic Genetically Engineered Mouse Goals Grant Hand Histopathology Human Image Immersion Immunity Immunohistochemistry Immunooncology Immunotherapy Industry Inflammation Inflammatory Infrastructure Institutes Investments Journals Libraries Link Location Malignant Neoplasms Medical Methods Mission Molecular Genetics National Institute of Biomedical Imaging and Bioengineering New Agents Organic Synthesis Patient Care Patients Peptides Peptoids Pharmacology Phenotype Positron-Emission Tomography Preclinical Testing Process Radiology Specialty Reagent Recording of previous events Reporter Research Resources Schools Services Site System Technical Expertise Technology Training Transgenic Organisms Translating Translations United States National Institutes of Health Universities Validation Work anticancer research arm cancer cell cancer imaging cancer immunotherapy cellular imaging commercialization cost design flexibility handicapping condition human imaging imaging agent imaging modality imaging system immune checkpoint in vitro Model in vivo in vivo monitoring instrumentation lectures molecular imaging neuroinflammation next generation nuclear division phase II trial pre-clinical precision medicine programs radioligand radiotracer research and development side effect small molecule targeted agent technology development theranostics tumor tumor microenvironment web site

项目摘要

OVERALL RESOURCE: Summary The Resource for Molecular Imaging Agents in Precision Medicine is a program spanning three campuses of the Johns Hopkins University (JHU). In our view precision medicine is using all data at hand regarding a particular patient to enable the best possible care for that patient. We believe that carefully designed molecular imaging agents can contribute to this. We are now poised to offer a unique Biomedical Technology Resource Center (BTRC) with a heavy emphasis on the provision of chemistry – new reagents, methods and training in their development and practice – for molecular imaging. The biological theme of the BTRC is relationships between cancer, inflammation and immunity, deeper study of which is an unmet need. Although brilliant research continues worldwide in the development of new molecular imaging agents, few have had actual impact on addressing human infirmity and many do not justify the cost of their development. In March 2014 the NIBIB conducted a study “to better understand the reasons why more molecular imaging agents and instrumentation developed with NIH grant support are not being translated to the clinic nor subsequently commercialized.” To address those shortcomings, the JHU BTRC will be highly translational by leveraging the Center for Translational Molecular Imaging (CTMI) at the Johns Hopkins Bayview medical campus, the F. M. Kirby Center for Functional Brain Imaging at the Kennedy Krieger Institute, the Division of Cancer Imaging Research, and the Division of Nuclear Medicine and Molecular Imaging, all of which are highly integrated into numerous departments and schools at JHU. We have generated agents that have been licensed and are in the process of commercialization. However to date those activities have been performed on an ad hoc basis, and we intend to expand upon them in two new ways: (1) provide targeted and unique technical research and development (TR&D) projects that will (2) enable widespread dissemination and training in their use, enhancing the capacity of the centers and divisions noted above to perform their intended functions – discovery with intent to educate, promote new collaborative, transdisciplinary research and to manage a variety of conditions, while addressing unanticipated effects of emerging cancer immunotherapies. The unique aspect of the BTRC is its focus on provision of new, precision materials, to test these pre-clinically and progress them to human use, delivered on-site or to our collaborators in a format suitable for their implementation. We will assure proper off-site utilization through continual, reciprocal education and “push-pull” interactions. The program is agnostic to imaging modality and composition of the materials to provide, relying upon the specific expertise within each TR&D. In addition to sharing the goal of leveraging chemistry for imaging, the four TR&Ds will be linked through the aforementioned biological theme. They can briefly be summarized as focusing on new theranostics (TR&D 1), molecular-genetic imaging systems (TR&D 2), agents for probing immunity (TR&D 3), and targeted agents for chemical exchange saturation transfer (CEST, TR&D 4). Within TR&Ds 1 and 3 are also the Pre-clinical and Clinical Validation cores, respectively.

总体资源：摘要精密医学中分子成像剂的资源是一个跨越三个校园的程序约翰·霍普金斯大学（JHU）。在我们看来，精确医学正在使用有关特定的所有数据患者可以为该患者提供最佳护理。我们相信精心设计的分子成像代理商可以为此做出贡献。现在，我们被毒品提供了一个独特的生物医学技术资源中心（BTRC）强调化学的提供 - 新试剂，方法和培训开发和实践 - 用于分子成像。 BTRC的生物学主题是癌症，炎症和免疫力，更深入的研究是未满足的需求。虽然很棒的研究在全球范围内，在新分子成像剂的发展中，很少有人对解决人类患病的问题，许多人不能证明其发展的成本是合理的。 2014年3月尼比布进行了一项研究“以更好地理解更多分子成像剂和仪器的原因以NIH的赠款支持开发，没有被转化为诊所，也不会被商业化。” 解决这些缺点，JHU BTRC将通过利用翻译中心来高度翻译 Johns Hopkins Bayview Medical Campus的分子成像（CTMI），F。M。Kirby功能中心肯尼迪·克里格研究所（Kennedy Krieger Institute）的脑成像，癌症成像研究部和核医学和分子成像，所有这些都高度整合到众多部门中 Jhu的学校。我们已经生成了已获得许可并正在商业化过程中的代理商。但是，迄今为止，这些活动已临时进行，我们打算扩大它们通过两种新的方式：（1）提供针对性的独特技术研发（TR＆D）项目（2）在其使用中启用宽度传播和培训，增强了中心和部门的能力上面注意到的是执行其预期功能 - 意图进行教育，促进新的合作活动，跨学科研究并管理各种条件，同时解决了新兴的癌症免疫疗法。 BTRC的独特方面是其专注于提供新的精确度材料，预先链接地测试这些并将其推向人类使用，现场交付或我们的合作者以适合其实施的格式。我们将通过连续的，倒数地假设适当的场外利用教育和“推力”互动。该程序对成像方式和组成不可知提供的材料，依靠每个TR＆D中的特定专业知识。除了分享目标利用化学成像，四个TR＆D将通过近似生物学主题链接。可以简要地总结为重点关注新的Theranostics（TR＆D 1），分子遗传成像系统（TR＆D 2），探测免疫力的药物（TR＆D 3），以及用于化学交换满意度转移的靶向代理（Cest，TR＆D 4）。在TR＆D 1和3中，也分别是临床前和临床验证核心。

项目成果

期刊论文数量（46）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Acoustic-resolution photoacoustic microscope based on compact and low-cost delta configuration actuator.

DOI：
10.1016/j.ultras.2021.106549
发表时间：
2022-01
期刊：
Ultrasonics
影响因子：
4.2
作者：
Gao S;Tsumura R;Vang DP;Bisland K;Xu K;Tsunoi Y;Zhang HK
通讯作者：
Zhang HK

Carbon Dots as a New Class of Diamagnetic Chemical Exchange Saturation Transfer (diaCEST) MRI Contrast Agents.

DOI：
10.1002/anie.201904722
发表时间：
2019-06
期刊：
Angewandte Chemie
影响因子：
0
作者：
Jia Zhang;Yue Yuan;Minling Gao;Zheng Han;Chengyan Chu;Yuguo Li;P. V. van Zijl;M. Ying;J. Bulte;Guanshu Liu
通讯作者：
Jia Zhang;Yue Yuan;Minling Gao;Zheng Han;Chengyan Chu;Yuguo Li;P. V. van Zijl;M. Ying;J. Bulte;Guanshu Liu

6-O-(2-[18F]Fluoroethyl)-6-O-Desmethyl-Diprenorphine ([18F]FE-DPN) Preferentially Binds to Mu Opioid Receptors In Vivo.

6-O-(2-[18F]氟乙基)-6-O-去甲基-二丙诺啡 ([18F]FE-DPN) 在体内优先与 Mu 阿片受体结合。

DOI：
10.1007/s11307-022-01767-5
发表时间：
2023
期刊：
Molecular imaging and biology
影响因子：
3.1
作者：
Levinstein,MarjorieR;Ventriglia,EmilyaN;Gomez,JuanL;Budinich,ReeceC;Marton,János;Henriksen,Gjermund;Holt,DanielP;Dannals,RobertF;Pomper,MartinG;ZarateJr,CarlosA;Bonaventura,Jordi;Michaelides,Michael
通讯作者：
Michaelides,Michael

A Unique Core-Shell Structured, Glycol Chitosan-Based Nanoparticle Achieves Cancer-Selective Gene Delivery with Reduced Off-Target Effects.